The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
Abstract
Purpose: To define patterns of survival among all multiple myeloma (MM) patients diagnosed in Sweden during a 30-year period. Patients and Methods: A total of 14,381 MM patients (7,643 males; 6,738 females) were diagnosed in Sweden from 1973 to 2003 (median age, 69.9 years; range 19 to 101 years). Patients were categorized into six age categories and four calendar periods (1973 to 1979, 1980 to 1986, 1987 to 1993, and 1994 to 2003). We computed relative survival ratios (RSRs) as measures of patient survival. Results: One-year survival improved (P < .001) over time in all age groups and RSRs were 0.73, 0.78, 0.80, and 0.82 for the four calendar periods; however, improvement in 5-year (P < .001) and 10-year (P < .001) RSR was restricted to patients younger than 70 years and younger than 60 years, respectively. For the first time, in analyses restricted to MM patients diagnosed at age younger than 60 years, we found a 29% (P < .001) reduced 10-year mortality in the last calendar period (1994 to 2003) compared with the preceding calendar period (1987 to 1993). Females with MM had a 3% (P = .024) lower excess mortality than males. Conclusion: One-year MM survival has increased for all age groups during the last decades; 5-year and 10-year MM survival has increased in younger patients (younger than 60 to 70 years). High-dose melphalan with subsequent autologous stem-cell transplantation, thalidomide, and a continuous improvement in supportive care measures are probably the most important factors contributing to this finding. New effective agents with a more favorable toxicity profile are needed to improve survival further, particularly in the elderly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Regression models for relative survival
Dickman, P. W., Sloggett, A., Hills, M., & Hakulinen, T. (2004) · Statistics in Medicine · doi:10.1002/sim.1597 · Cited by 792
Self-citationEffective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
Mattsson, B., & Wallgren, A. (1984) · Acta Radiologica: Oncology · doi:10.3109/02841868409136026 · Cited by 559
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Interpreting trends in cancer patient survival
DICKMAN, P. W., & ADAMI, H. ‐. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01677.x · Cited by 508
Self-citationTreatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens
Alexanian, R. (1969) · JAMA · doi:10.1001/jama.208.9.1680 · Cited by 499
Barlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Augustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Cancer Survival Corrected for Heterogeneity in Patient Withdrawal
Hakulinen, T. (1982) · Biometrics · doi:10.2307/2529873 · Cited by 453
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0551 · Cited by 399
Jagannath, S., Durie, B. G. M., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05540.x · Cited by 398
Treatment for Multiple Myeloma: Combination Chemotherapy With Different Melphalan Dose Regimens
Alexanian, R. (1969) · JAMA · doi:10.1001/jama.1969.03160090040009 · Cited by 393
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 340
Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., De Laurenzi, A., Facon, T., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02726.x · Cited by 340
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
INTERFERON THERAPY IN MYELOMATOSIS
Mellstedt, H., Björkholm, M., Johansson, B., Ahre, A., Holm, G., & Strander, H. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90770-0 · Cited by 275
Self-citationCentralised treatment, entry to trials and survival
Stiller, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.306 · Cited by 247
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242
The Myeloma Trialists' Collaborative Group (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02857.x · Cited by 217
Henson, D. E., & Ries, L. A. (1995) · Cancer · doi:10.1002/1097-0142(19951115)76:10<1687::aid-cncr2820761002>3.0.co;2-i · Cited by 158
Centralisation of treatment and survival rates for cancer.
Stiller, C. A. (1988) · Archives of Disease in Childhood · doi:10.1136/adc.63.1.23 · Cited by 146
Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia.
Stiller, C. A., & Draper, G. J. (1989) · Archives of Disease in Childhood · doi:10.1136/adc.64.5.657 · Cited by 132
Bergsagel, D. E., Cc, S., AUSTIN, C., & Griffith, K. M. (1962) · PubMed · Cited by 125
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
Berger, U., Maywald, O., Pfirrmann, M., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403756 · Cited by 89
Wang, L. H., Yang, X. Y., Mihalic, K., Xiao, W., Li, D., & Farrar, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105185200 · Cited by 85
Lenhoff, S., Hjorth, M., Westin, J., Brinch, L., Bäckström, B., Carlson, K. E., Christiansen, I., Dahl, I. M. S., Gimsing, P., Hammerstrøm, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06042.x · Cited by 73
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
Turesson, Abildgaard, Ahlgren, Dahl, Holmberg, Hjorth, Nielsen, Odén, Seidel, Waage, et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01651.x · Cited by 68
Multiple myeloma in elderly patients: prognostic factors and outcome
Anagnostopoulos, A., Gika, D., Symeonidis, A. S., Zervas, K., Pouli, A. G., Repoussis, P., Grigoraki, V., Anagnostopoulos, N. I., Economopoulos, T., Maniatis, A. G., et al. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00532.x · Cited by 61
Landgren, O., Zhang, Y., Zahm, S. H., Inskip, P. D., Zheng, T., & Baris, D. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0097 · Cited by 59
Self-citationLenhard, R. E., Enterline, J. P., Crowley, J. J., & Ho, G. Y. F. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1640 · Cited by 48
Intermittent Melphalan and Prednisolone Therapy in Plasma Cell Myeloma
Mellstedt, H., Björkholm, M., & Holm, G. (1977) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1977.tb16773.x · Cited by 46
Self-citationÅhre, A., Björkholm, M., Mellstedt, H., Holm, G., Brenning, G., Engstedt, L., Gahrton, G., Hällén, J., Johansson, B., Johansson, S., et al. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90113-x · Cited by 28
Self-citationJohnsen, H. E., Björkstrand, B., Carlson, K. E., Gruber, A., Blystad, A. K., Fast, A., Boesen, A. M., Björkholm, M., Sallerfors, B., Ruutu, T., et al. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609045716 · Cited by 15
Self-citationHjorth, M., Holmberg, E. C., Rödjer, S., Taube, A., & Westin, J. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05254.x · Cited by 15
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C., Holmberg, E., Mellqvist, U.-H., Landgren, O., Bjorkholm, M., Hultcrantz, M., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2015) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 524
Self-citation
Metadata
- Authors
- Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-05-20
- Volume
- 25
- Issue
- 15
- Pages
- 1993-1999
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2132392953
- Cited by
- 319
- References
- 48
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.